S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

PYC Therapeutics Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive PYC News and Ratings via Email

Sign-up to receive the latest news and ratings for PYC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About PYC Therapeutics

PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.


No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
$3.07 million
Book Value
A$0.02 per share





Next Earnings Date
Not Optionable


Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

PYC Therapeutics (ASX:PYC) Frequently Asked Questions

What stocks does MarketBeat like better than PYC Therapeutics?

Wall Street analysts have given PYC Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PYC Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are PYC Therapeutics' key executives?

PYC Therapeutics' management team includes the following people:
  • Dr. Rohan Hockings MBBS, MBBS (Hons.), J.D., G.D.L.P, CEO & Director (Age 38, Pay $395k)
  • Mr. Kevin Ronald Hart B.Com., F.C.A., B.Comm (Hons), FCA, Company Sec. & CFO (Age 59)
  • Prof. Sue Fletcher, Chief Scientific Officer
  • Mr. Sahm Nasseri M.B.A., MBA, CEO of US operations & Director (Age 37)
  • Mr. Kaggen Ausma L.L.B., Chief Bus. Officer
  • Dr. May Orfali, Chief Medical Officer of US Operations
  • Dr. Glenn Noronha, Chief Devel. Officer (Age 56)

What is PYC Therapeutics' stock symbol?

PYC Therapeutics trades on the ASX under the ticker symbol "PYC."

How much money does PYC Therapeutics make?

PYC Therapeutics has a market capitalization of $0.00 and generates $3.07 million in revenue each year.

What is PYC Therapeutics' official website?

The official website for PYC Therapeutics is pyctx.com.

How can I contact PYC Therapeutics?

The company can be reached via phone at 61 8 6151 0992.

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.